Due to the increase in the incidence of lung cancer among elderly individuals, the efficacy and safety of EGFR-TKIs for the treatment of elderly patients with non-small-cell lung cancer (NSCLC) have been investigated in previous clinical trials (3–7), although those in clinical practice have not yet been evaluated. This evidence concerns the gene EGFR and non-small cell lung carcinoma.